What's driving Cancer Gene Therapy Market ; Eminent Players - SiBiono., Shanghai Sunway Biotech company limited, Altor Bioscience Corporation, Amgen, BioCancell, Aduro Biotech, OncoGeneX, GlobeImmune, Inc., New Link Genetics., MolMed S.p.A, ZioPharm Oncol

Cancer Gene Therapy Market size is expected to exceed USD 4.3 billion by 2024; as per a new research report by Global Market Insights, Inc. Increased adoption of emerging genomic technologies such as NGS and high density micro array coupled with favorable government initiatives will fuel global cancer gene therapy market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance. However, high cost of development lack of reimbursement and regulatory processes will restrain industry growth.

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/763

Growing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new treatment modalities to help make cancer a manageable disease. By the end of 2012, the number of clinical trials crossed 1,800 worldwide.

Adenoviral vector remains as the most common oncology application due to its competent nuclear mechanism and low pathogenicity. It is widely used in replacement approaches, suicide and gene-based immunotherapy, and syndicate with chemotherapy and is anticipated to grow at 20% CAGR.

Retroviral vector-mediated gene transfer dominated the development by enabling the conversion of single stranded RNA into a double stranded DNA molecule, which steadily integrates into the target cell genome. These vectors are used to permanently modify the host cell nuclear genome and will register a robust growth of over 20%.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/763

U.S. led the industry owing to increased R&D funding and other government initiatives. Growing number of biotech companies are engaging in R&D and clinical trials of gene therapy products. Increased demand for DNA vaccines and increasing interest of venture capitalists to invest in commercialization of gene therapies will trigger industry expansion.

China cancer gene therapy market size attributed to over 35% APAC revenue in 2015. With the launch of Gendicine and increasing healthcare expenditure and robust R&D facilities will enable industry growth.

Key insights from the report include:

• U.S. cancer gene therapy market share accounted for over 95% regional revenue in 2015, with market size of USD 235 million and a forecast to grow at 20.9% CAGR.

• UK was over USD 92.0 million in 2015, and will grow at 20.8% CAGR owing to increasing incidence of cancer and adoption of advanced treatment methods.

• China market size was valued at USD 99.6 million in 2015 and growth expectations of 21% CAGR over the forecast years.

• Key players include SiBiono, Altor Bioscience Corporation, Shanghai Sunway Biotech company limited, Amgen, BioCancell, OncoGeneX, Aduro Biotech, GlobeImmune, Inc., New Link Genetics., ZioPharm Oncology, MolMed, GENELUX, Gradalis, MultiVir.

• The industry is highly fragmented and is dominated by several small biotech firms collectively accounting for over 80% of cancer gene therapy market pipeline. Major growth strategies adopted by these small firms include, technology transfer, licensing and commercialization deals, strategic collaborations and mergers and acquisitions to retain their industry position.

Report Content

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.1.1. Initial data exploration
1.1.2. Statistical modeling and forecast
1.1.3. Industry insights and validation
1.1.4. Research scope & assumptions
1.2. Data Sources

Chapter 2. Executive Summary
2.1. Cancer genetics industry 3600 synopsis, 2012 - 2024
2.1.1. Business trends
2.1.2. Regional trends
2.1.3. Application trends

Chapter 3. Cancer Gene Therapy Industry Insights
3.1. Industry segmentation
3.2. IIndustry Size and forecast, 2012 - 2024
3.3. Industry Impact forces
3.3.1. Growth drivers
3.3.1.1. Technological advancements
3.3.1.2. Increased adoption of nanotechnology
3.3.1.3. Favorable government regulations
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of cancer genetherapy
3.4. Growth potential analysis
3.5. Porter’s analysis
3.6. Key opportunities prioritized, 2015
3.7. PESTEL analysis
3.8. Regulatory Landscape
3.8.1. U.S.
3.8.2. EU
3.8.3. China
3.9. Scientific and Ethical issues in Gene Therapy
3.10. Competitive landscape, 2015
3.11. Pipeline Analysis by cancer type
3.11.1. Head and Neck Cancer Pipeline Analysis
3.11.2. Breast Cancer Pipeline Analysis
3.11.3. Gastro Intestinal Cancer Pipeline Analysis
3.11.4. Gentiourinary Cancer Pipeline Analysis
3.11.5. Gynecological Cancer Pipeline Analysis
3.11.6. Haemotological Cancer Pipeline Analysis
3.11.7. Neurologic Cancer Pipeline Analysis
3.11.8. Respiratory Cancer Pipeline Analysis
3.11.9. Skin Cancer Pipeline Analysis

Chapter 4. Cancer Gene Therapy Insights
4.1. Cancer gene therapy market share by therapy, 2015 & 2024
4.2. Gene Induced Immunotherapy
4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.2. Delivery of cytokine gene
4.2.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.3. Delivery of tumor antigen gene
4.2.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3. Oncolytic Virotherapy
4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.2. Adenoviruses
4.3.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.3. Lentiviruses
4.3.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.4. Retrovirus
4.3.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.5. Adeno Associated Virus
4.3.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.6. Herpes Simplex Virus
4.3.6.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.7. Alphavirus
4.3.7.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.8. Vaccinia Virus
4.3.8.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.9. Simian Virus
4.3.9.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.10. Others
4.3.10.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4. Gene transfer/ Gene replacement
4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.2. Naked/Plasmid Vectors
4.4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.3. Electroporation
4.4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.4. Sonoportion
4.4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.5. Magnetofection
4.4.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.6. Gene Gun
4.4.6.1. Market estimates and forecast, 2012-2024 (USD Million)

Charts & Figures

FIG. 1 Industry Segmentation
FIG. 2 Global cancer gene therapy market, 2012–2024 (USD Million)
FIG. 3 Industry Impact forces
FIG. 4 Growth potential analysis
FIG. 5 Cancer gene therapy market Porter’s analysis
FIG. 6 Cancer gene therapy market PESTEL analysis

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Blog : http://news-researchers.com/

This release was published on openPR.